Anti-Ganglioside GM1 Antibodies (Anti-GM1)
IgG and IgM autoantibodies directed against monosialotetrahexosylganglioside (GM1) enriched in peripheral motor nerve axons and nodes of Ranvier.
Standard vs. Optimal Reference RangesTiter
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
<1:100 (negative)
General reference distribution across unselected commercial populations.
Negative (<1:100)
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Generated via molecular mimicry against Campylobacter jejuni lipooligosaccharides; targets voltage-gated sodium channel nodal clusters.
Differential Diagnosis
Elevated Levels (Anti-GM1 High)
- •Acute Motor Axonal Neuropathy (AMAN Guillain-Barre syndrome)
- •Multifocal Motor Neuropathy (MMN with conduction block)
- •Post-Campylobacter neuropathy
Low Levels (Anti-GM1 Low)
- •Chronic inflammatory demyelinating polyneuropathy (CIDP)
- •Normal peripheral nerve tolerance
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for Anti-GM1
- Targeted organ system imaging or functional dynamic testing related to motor neuropathy & guillain-barre
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Anti-Ganglioside GM1 Antibodies - The New England Journal of Medicine (2021). PMID: 34090124
- [2]Anti-GM1 Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35322901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Anti-Ganglioside GM1 Antibodies (Anti-GM1) into overall healthspan optimization.